摘要:
Human ciliary neurotrophic factor (human CNTF) mutants, in which at least the amino acid residue corresponding to position 153 of wild type human CNTF has been substituted with another amino acid residue in the amino acid sequence encoding human CNTF, exhibit an activity comparable or superior to that of wild type human CNTF. It is therefore expected that the human CNTF mutants would be effective as drugs with improved side effects such as reduction in appearance of an autoantibody, loss of body weight, anorexia, a dry cough, fatigue, etc.In cytokines having sequence similarity to human CNTF and abundant .alpha. helices (GH, PRL, EPO, G- CSF, LIF, IL-6, IL-2, IL-4, GM-CSF), there are further provided mutants in the D1 cap region.
摘要:
Modified BDNF having improved pharmacological activities, pharmacokinetics and physical properties can be obtained by modifying BDNF with a 1-acyl-glycerol derivative. This BDNF being modified with a 1-acyl-glycerol derivative of the present invention has more efficacious and more excellent pharmacokinetic properties with retaining the useful effects being characteristic to BDNF which are useful as remedies for neurodegenerative diseases and diabetes mellitus, and hence, it is particularly useful as a therapeutic agent for treatment of type 2 diabetes mellitus.
摘要:
The present invention provides a therapeutic agent for treatment of diabetes and hyperlipemia, especially a therapeutic agent for treatment of type II diabetes mellitus, which comprises as the active ingredient a neurotrophic factor such as BDNF (brain-derived neurotrophic factor), ligands of trkB or trkC receptors, NGF, NT-3, NT-4/5, CNTF, GDNF, HGF, etc. Different from conventional oral hypoglycemic agents being mainly used in the treatment of type II diabetes mellitus, the agent of the present invention exhibit blood lipid regulating effects and body fat accumulation regulating effects, in addition to the blood glucose regulating effects. Thus, the agent of the present invention are novel, and can reduce the risk factors in diabetes accompanied by hyperlipemia or obesity, without using any other agent.
摘要:
The present invention provides a therapeutic agent for treatment of diabetes and hyperlipemia, especially a therapeutic agent for treatment of type II diabetes mellitus, which comprises as the active ingredient a neurotrophic factor such as BDNF (brain-derived neurotrophic factor), ligands of trkB or trkC receptors, NGF, NT-3, NT-4/5, CNTF, GDNF, HGF, etc. Different from conventional oral hypoglycemic agents being mainly used in the treatment of type II diabetes mellitus, the agent of the present invention exhibit blood lipid regulating effects and body fat accumulation regulating effects, in addition to the blood glucose regulating effects. Thus, the agent of the present invention are novel, and can reduce the risk factors in diabetes accompanied by hyperlipemia or obesity, without using any other agent.
摘要:
A motion vector detector detects a motion vector, and outputs a block matching error value. An entire scroll determiner generates an entire scroll degree. Based on the block matching error value, a reliability generator generates reliability data indicating reliability of the motion vector. A reliability adjuster adjusts the reliability data so that a value of the reliability data is larger as the entire scroll degree is a value in which the degree at which the image scrolls entirely is larger, and outputs adjusted reliability data. Based on the adjusted reliability data, the interpolation pixel generator generates respective interpolation pixels composing a motion compensated frame.
摘要:
A motion vector detector 2 detects, using pixel data in at least two real frames in an input video signal, a motion vector MV1 necessary for generating interpolated pixel data forming an interpolated frame to be inserted between the two real frames. A motion vector corrector 4 corrects the motion vector MV1 to decrease the magnitude of motion vector MV1 when the magnitude of motion vector MV1 exceeds a predetermined threshold, and outputs it as a motion vector MV3.
摘要:
An inactivating device for inactivating virus, bacteria, etc. including a humidifying unit for humidifying flowing air, a humidifying water supply unit for supplying the humidifying unit with humidifying water containing active oxygen species achieved by electrolyzing tap water, and a concentration adjusting unit for adjusting the concentration of the active oxygen species in the humidifying water to a predetermined concentration.
摘要:
Preparations to be administered for treating or preventing ischemic diseases or arterial diseases which contain Hepatocyte growth factor (HGF) as an active ingredient. The preparations provide such effect that HGF concentration in an affected region to which HGF was administered is maintained, a half-life is longer, a dose can be reduced, and other organs except the affected region are less affected in comparison with intravenous administration.
摘要:
A humanized antibody is provided, which is obtained by transplantation of the complementarity determining region of a mouse monoclonal antibody B-B10 specific to a human IL-2 receptor into a human antibody. The antibody has a very low antigenicity, and therefore, it is useful for treatment of carcinoma expressing IL-2 receptor.
摘要:
A process for preparing a metal phenolate of the formula II:Cl--Ar.sub.1 COAr.sub.2 OM (II)wherein each of Ar.sub.1 and Ar.sub.2 which may be the same or different is a bivalent group of the formula: ##STR1## wherein each of R.sup.1 and R.sup.12 is a hydrogen atom, a halogen atom, an alkoxy group, a phenoxy group, an alkyl group, a cycloalkyl group, a phenyl group, an aralkyl group, an acyl group, a nitrile group, a nitro group or an acyloxy group, each of Y and Z is an oxygen atom or a ketone group, and each of n and m is an integer of from 0 to 4, and M is an alkali metal, which comprises reacting a phenol compound of the formula I:Cl--Ar.sub.1 COAr.sub.2 OH (I)wherein Ar.sub.1 and Ar.sub.2 are as defined above, with an alkali metal compound in the presence of water, and then removing water, characterized in that water is azeotropically distilled off together with an organic solvent capable of forming an azeotropic mixture with water.